TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
3.975
-0.145 (-3.52%)
Nov 21, 2024, 12:13 PM EST - Market open
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 11.4, with a low estimate of 9.00 and a high estimate of 15. The average target predicts an increase of 186.79% from the current stock price of 3.98.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TCRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +277.36% | Nov 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +176.73% | Nov 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +176.73% | Nov 6, 2024 |
| Wedbush | Wedbush | Buy Reiterates $10 | Buy | Reiterates | $10 | +151.57% | Aug 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +277.36% | Aug 13, 2024 |
Financial Forecast
Revenue This Year
3.51M
from 21.05M
Decreased by -83.32%
Revenue Next Year
3.62M
from 3.51M
Increased by 3.10%
EPS This Year
-1.21
from -1.87
EPS Next Year
-1.31
from -1.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.4M | 10.5M | 25.6M | ||
| Avg | 3.5M | 3.6M | 8.7M | ||
| Low | 2.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -69.6% | 199.0% | 606.5% | ||
| Avg | -83.3% | 3.1% | 139.8% | ||
| Low | -90.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.12 | -1.17 | -1.13 | ||
| Avg | -1.21 | -1.31 | -1.45 | ||
| Low | -1.26 | -1.67 | -1.88 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.